0000874015-19-000047.txt : 20190301 0000874015-19-000047.hdr.sgml : 20190301 20190301174005 ACCESSION NUMBER: 0000874015-19-000047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190227 FILED AS OF DATE: 20190301 DATE AS OF CHANGE: 20190301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'NEIL PATRICK R. CENTRAL INDEX KEY: 0001564926 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 19650917 MAIL ADDRESS: STREET 1: C/O ISIS PHARMACEUTICALS, INC. STREET 2: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-02-27 0000874015 IONIS PHARMACEUTICALS INC IONS 0001564926 O'NEIL PATRICK R. C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP Legal & General Counsel Common Stock 2019-02-27 2019-02-27 4 M 0 4700 47.34 A 24373 D Common Stock 2019-02-27 2019-02-27 4 S 0 4700 64.5116 D 19673 D Common Stock 2019-02-27 2019-02-27 4 M 0 14100 47.34 A 33773 D Common Stock 2019-02-27 2019-02-27 4 S 0 14100 68.75 D 19673 D Common Stock 2019-02-27 2019-02-27 4 M 0 8000 39.87 A 27673 D Common Stock 2019-02-27 2019-02-27 4 S 0 8000 68.75 D 19673 D Employee Stock Option (right to buy) 47.34 2019-02-27 2019-02-27 4 M 0 18800 0 A 2019-01-03 2024-01-02 Common Stock 18800 4755 D Employee Stock Option (right to buy) 39.87 2019-02-27 2019-02-27 4 M 0 8000 0 A 2018-01-02 2021-01-01 Common Stock 8000 0 D Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.50 to $64.55, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Patrick R. O'Neil 2019-03-01